Tirilazad

Drug Profile

Tirilazad

Alternative Names: Freedox; Tirilazad mesylate; U 74006A; U 74006F; U 74389F

Latest Information Update: 19 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Pregnatrienes
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Subarachnoid haemorrhage
  • Discontinued Craniocerebral trauma; Ischaemic heart disorders; Kidney disorders; Spinal cord injuries; Stroke; Transplant rejection

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 28 May 1999 Tirilazad has failed to gain recommendation for approval by the US FDA for the treatment of aneurysmal subarachnoid haemorrhage
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top